Tuesday , August 4 2020
Home / Business / International Business / Coronavirus treatment drug remdesivir to arrive US hospitals this week, says Gilead CEO

Coronavirus treatment drug remdesivir to arrive US hospitals this week, says Gilead CEO

Spread the love

Remdesivir, the first possible scientifically proven treatment for battling COVID-19, will become available for U.S. hospitals in the coming week, says the CEO of the biotech company producing the drug.

Daniel O’Day, CEO and chairman of Gilead Sciences, provided the update Sunday on the CBS News program “Face the Nation.” He said that the Foster City, California-headquartered company had donated 1.5 million vials to the U.S. government, enough to treat 150,000 to 200,000 patients.

Daniel O’Day, CEO and chairman of Gilead Sciences, provided the update Sunday on the CBS News program “Face the Nation.” He said that the Foster City, California-headquartered company had donated 1.5 million vials to the U.S. government, enough to treat 150,000 to 200,000 patients.

The company is also attempting to develop other delivery methods for the drug, which is given via an IV and blocks an enzyme the virus uses to copy its genetic material. Gilead hopes to develop a shot that can be given outside o the hospital “or possibly an inhaled version,” O’Day said.

“This medicine is not suitable for oral administration because of the way it is metabolized, but there are ways we can look at formulations potentially that would get us to earlier patients and patients outside the hospital setting,” he said.

 

This article originally appeared on USA TODAY: Coronavirus treatment drug remdesivir to arrive in hospitals this week, Gilead CEO says

About Charles Igbinidu

Charles Igbinidu is a Public Relations practitioner in Lagos, Nigeria

Check Also

 Chelsea owner Roman Abramovich agrees to sell stake worth £1billion

Spread the loveRussian billionaire and Chelsea owner, Roman Abramovich is set to get richer, as …

Leave a Reply

Your email address will not be published. Required fields are marked *